Orchard Therapeutics plc [NASDAQ: ORTX] jumped around 0.56 points on Friday, while shares priced at $4.93 at the close of the session, up 12.81%. The company report on December 8, 2020 that Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA).
Preliminary results from first patient treated with OTL-201 show over expression of the therapeutic enzyme and decrease in substrate levels three months following gene therapy.
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-201, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy being studied for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A). The data were presented as part of an oral presentation given yesterday at the 62nd American Society of Hematology (ASH) Annual Meeting.
Orchard Therapeutics plc stock is now -64.15% down from its year-to-date (YTD) trading value. ORTX Stock saw the intraday high of $5.48 and lowest of $4.435 per share. The company’s 52-week high price is 15.93, which means current price is +31.12% above from all time high which was touched on 01/15/20.
Compared to the average trading volume of 679.74K shares, ORTX reached a trading volume of 3602888 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Orchard Therapeutics plc [ORTX]?
Oppenheimer have made an estimate for Orchard Therapeutics plc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on September 17, 2019, representing the official price target for Orchard Therapeutics plc stock.
The Average True Range (ATR) for Orchard Therapeutics plc is set at 0.38, with the Price to Sales ratio for ORTX stock in the period of the last 12 months amounting to 133.50. The Price to Book ratio for the last quarter was 2.37, with the Price to Cash per share for the same quarter was set at 2.32.
How has ORTX stock performed recently?
Orchard Therapeutics plc [ORTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.79. With this latest performance, ORTX shares gained by 14.12% in over the last four-week period, additionally sinking by -26.64% over the last 6 months – not to mention a drop of -67.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORTX stock in for the last two-week period is set at 58.28, with the RSI for the last a single of trading hit 62.92, and the three-weeks RSI is set at 55.47 for Orchard Therapeutics plc [ORTX]. The present Moving Average for the last 50 days of trading for this stock 4.51, while it was recorded at 4.57 for the last single week of trading, and 6.42 for the last 200 days.
Orchard Therapeutics plc [ORTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Orchard Therapeutics plc [ORTX] shares currently have an operating margin of -7578.07 and a Gross Margin at +1.31. Orchard Therapeutics plc’s Net Margin is presently recorded at -6503.06.
Return on Total Capital for ORTX is now -58.26, given the latest momentum, and Return on Invested Capital for the company is -50.45. Return on Equity for this stock declined to -53.76, with Return on Assets sitting at -42.88. When it comes to the capital structure of this company, Orchard Therapeutics plc [ORTX] has a Total Debt to Total Equity ratio set at 15.34. Additionally, ORTX Total Debt to Total Capital is recorded at 13.30, with Total Debt to Total Assets ending up at 11.50. Long-Term Debt to Equity for the company is recorded at 13.38, with the Long-Term Debt to Total Capital now at 11.60.
Reflecting on the efficiency of the workforce at the company, Orchard Therapeutics plc [ORTX] managed to generate an average of -$651,185 per employee. Receivables Turnover for the company is 0.17 with a Total Asset Turnover recorded at a value of 0.01.Orchard Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.70 and a Current Ratio set at 5.70.
Earnings analysis for Orchard Therapeutics plc [ORTX]
With the latest financial reports released by the company, Orchard Therapeutics plc posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.44/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORTX.
Insider trade positions for Orchard Therapeutics plc [ORTX]
There are presently around $319 million, or 68.00% of ORTX stock, in the hands of institutional investors. The top three institutional holders of ORTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 12,315,213, which is approximately 18.379% of the company’s market cap and around 0.23% of the total institutional ownership; FMR LLC, holding 12,244,590 shares of the stock with an approximate value of $60.37 million in ORTX stocks shares; and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), currently with $34.26 million in ORTX stock with ownership of nearly -4.278% of the company’s market capitalization.
Positions in Orchard Therapeutics plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 33 institutional holders increased their position in Orchard Therapeutics plc [NASDAQ:ORTX] by around 4,523,699 shares. Additionally, 43 investors decreased positions by around 7,955,545 shares, while 14 investors held positions by with 52,228,489 shares. The mentioned changes placed institutional holdings at 64,707,733 shares, according to the latest SEC report filing. ORTX stock had 10 new institutional investments in for a total of 69,815 shares, while 18 institutional investors sold positions of 953,376 shares during the same period.